United Therapeutics (UTHR) Net Cash Flow (2009 - 2026)

United Therapeutics has disclosed Net Cash Flow across 18 years of filings, most recently posting $523.5 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 270.63% year-over-year to $523.5 million; the TTM figure through Jun 2026 stood at $210.1 million (down 11.5% YoY), while the FY2025 annual figure was -$140.1 million, down 128.62% from the prior year.
• Net Cash Flow came in at $523.5 million for Q2 2026 at United Therapeutics, up from -$277.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $523.5 million in Q2 2026 to a low of -$306.8 million in Q2 2025.
• Average Net Cash Flow over 5 years is $50.5 million, with a median of $71.9 million recorded in 2023.
• The largest YoY upside for Net Cash Flow was 1885.71% in 2023 against a maximum downside of 431.49% in 2023.
• Over 5 years, Net Cash Flow stood at -$5.6 million in 2022, then soared by 1885.71% to $100.0 million in 2023, then soared by 43.3% to $143.3 million in 2024, then surged by 51.43% to $217.0 million in 2025, then jumped by 141.24% to $523.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $523.5 million in Q2 2026, -$277.4 million in Q1 2026, and $217.0 million in Q4 2025.